GABA<sub>B</sub> Receptors in the Centromedian/Parafascicular Thalamic Nuclear Complex: An Ultrastructural Analysis of GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 in the Monkey Thalamus

ROSA M. VILLALBA,1,* DINESH V. RAJU,1 RANDY A. HALL,2 AND YOLAND SMITH1,3
1Yerkes National Primate Research Center, Emory University, Atlanta, Georgia 30322
2Department of Pharmacology, Emory University, Atlanta, Georgia 30322
3Department of Neurology, Emory University, Atlanta, Georgia 30322

ABSTRACT

Strong γ-aminobutyric acid type B (GABA<sub>B</sub>) receptor binding has been shown throughout the thalamus, but the distribution of the two GABA<sub>B</sub> receptor subunits, GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2, remains poorly characterized. In primates, the caudal intralaminar nuclei, centromedian and parafascicular (CM/PF), are an integral part of basal ganglia circuits and a main source of inputs to the striatum. In this study, we analyzed the subcellular and subsynaptic distribution of GABA<sub>B</sub> receptor subunits by using light and electron microscopic immunocytochemical techniques. Quantitative immunoperoxidase and immunogold analysis showed that both subunits display a similar pattern of distribution in CM/PF, being expressed largely at extrasynaptic and perisynaptic sites in neuronal cell bodies, dendrites, and axon-like processes and less abundantly in axon terminals. Postsynaptic GABA<sub>B</sub>R1 labeling was found mostly on the plasma membrane (70–80%), whereas GABA<sub>B</sub>R2 was more evenly distributed between the plasma membrane and intracellular compartments of CM/PF neurons. A few axon terminals forming symmetric and asymmetric synapses were also labeled for GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2, but the bulk of presynaptic labeling was expressed in small axon-like processes. About 20% of presynaptic vesicle-containing dendrites of local circuit neurons displayed GABA<sub>B</sub>R1/R2 immunoreactivity. Vesicular glutamate transporters (vGluT1)-containing terminals forming asymmetric synapses expressed GABA<sub>B</sub>R1 and/or displayed postsynaptic GABA<sub>B</sub>R1 at the edges of their asymmetric specialization. Overall, these findings provide evidence for multiple sites where GABA<sub>B</sub> receptors could modulate GABAergic and glutamatergic transmission in the primate CM/PF complex.

© 2006 Wiley-Liss, Inc.

Indexing terms: immunocytochemistry; GABA<sub>B</sub>R1; GABA<sub>B</sub>R2; vGluT1; intralaminar thalamic nuclei; Parkinson’s disease

γ-Aminobutyric acid (GABA)-ergic neurotransmission is mediated by three distinct receptor subtypes, GABA<sub>A</sub>, GABA<sub>B</sub>, and GABA<sub>C</sub>, characterized by their pharmacological and electrophysiological properties. GABA<sub>A</sub> and GABA<sub>C</sub> receptors are ligand-gated chloride channels that mediate fast inhibitory postsynaptic currents by triggering the opening of integral chloride channels (Olsen and Tobin, 1990; Mcdonald and Olsen, 1994). GABA<sub>B</sub> receptors belong to the family of seven transmembrane domain receptors (Marshall et al., 1999) and are coupled to Ca<sup>2+</sup> and K<sup>+</sup> channels via G proteins and second messenger systems (Couve et al., 2000; Margeta-Mitrovic et al., 2000;
Billinton et al., 2001). Functional GABA<sub>R</sub> receptors were first identified on presynaptic terminals, where they act as auto- or heteroreceptors to influence transmitter release by suppressing Ca<sup>2+</sup> conductance (Bowery, 1993; Bowery et al., 2002). Subsequent studies showed the existence of postsynaptic GABA<sub>B</sub> receptors whose activation produces an increase in membrane K<sup>+</sup> conductance and associated neuronal hyperpolarization (for reviews see Bowery et al., 2002; Bettler et al., 2004; Cryan and Kaupmann, 2005). Thus, the synaptic release of GABA in a particular brain region can mediate distinct and complex electrophysiological effects depending on the relative abundance and distribution of the different subtypes of GABA receptors in relation to the release sites of transmitter.

So far, two GABA<sub>R</sub> receptor subunits have been identified, GABA<sub>R1</sub> receptor subunit 1 (GABA<sub>R1</sub>1) and GABA<sub>R</sub> receptor subunit 2 (GABA<sub>R2</sub>), which assemble into heterodimers to form functional GABA<sub>R</sub> receptors (Bettler et al., 1998; Jones et al., 1998; Kaumann et al., 1998; White et al., 1998; Kuner et al., 1999; Makoff, 1999; Martin et al., 1999; Bowery and Enna, 2000). The GABA<sub>R1</sub>R1 subunit is responsible for binding GABA, whereas GABA<sub>R2</sub>R2 is required for cell-surface expression (Bormann, 2000; Calver et al., 2001; Pagano et al., 2001) and G-protein coupling (Galvez et al., 2001; Margeta-Mitrovic et al., 2001a,b; Robbins et al., 2001; Havlickova et al., 2002) of GABA<sub>R</sub> receptors.

In situ hybridization and immunocytochemical studies revealed that GABA<sub>R1</sub>R1 and GABA<sub>R2</sub>R2 expression shows considerable overlap in many areas of the central nervous system (CNS; Margeta-Mitrovic et al., 1999; Clark et al., 2000). GABA<sub>R</sub> receptor binding sites, GABA<sub>R</sub> receptor subtype mRNAs, and GABA<sub>R</sub> receptor protein are strongly expressed in the rat and monkey thalamus (Chu et al., 1990; Muñoz et al., 1998; Ambardekar et al., 1999; Bowery et al., 1999; Princivalle et al., 2000, 2001), but their exact location and function remain controversial. Electrophysiological evidence indicates that GABA<sub>R</sub> may act as pre- or postsynaptic receptors at GABAergic and glutamatergic synapses in the rat and mouse thalamus (Banerjee and Snead, 1995; Ambardekar et al., 1999; Chen and Regehr, 2003). So far, a single electron microscopic analysis of the rat ventrobasal nucleus has examined the cellular and subcellular localization of GABA<sub>R</sub> receptor in the rat thalamus (Kulik et al., 2002).

In primates, the intralaminar nuclei, centromedian (CM) and parafascicular (PF), are an integral part of basal ganglia circuits (Smith et al., 2004). This nuclear group is a major source of thalamic afferents to the striatum (Cowan and Powell, 1956; Parent and DeBellefeuille, 1983; Smith and Parent, 1986) and receives functionally segregated GABAergic inputs from basal ganglia output nuclei (Smith et al., 2004). Despite this substantial GABAergic innervation, very little is known about the location and function of GABA<sub>R</sub> receptors in the caudal intralaminar complex.

To address this issue further, we undertook a detailed high-resolution electron microscopic study of the localization of GABA<sub>R1</sub>R1 and GABA<sub>R2</sub>R2 subunits in the monkey CM/PF. Findings of this study have been presented in part in abstract form (Villalba and Smith, 2004).

**MATERIALS AND METHODS**

**Animals and tissue preparation**

In total, seven rhesus monkeys (*Macaca mulatta*; Yerkes National Primate Research Center colony) and four Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) were used in this study. The experiments were performed according to the National Institutes of Health Guide for the care and use of laboratory animals. All efforts were made to minimize animal suffering and reduce the number of animals used.

For immunocytochemistry experiments, tissue was obtained from six adult monkeys and two rats. Animals were deeply anesthetized with an overdose of pentobarbital and perfused transcardially with cold, oxygenated Ringer’s solution, followed by fixative containing 4% paraformaldehyde and 0.1% glutaraldehyde in phosphate buffer (PB; 0.1 M, pH 7.4). After fixative perfusion, the brains were washed with PB, taken out from the skull, and cut into 10-mm-thick blocks in the frontal plane. Tissue sections (60 μm thick) were obtained with a Vibratome, collected in cold phosphate-buffered saline (PBS; 0.01 M, pH 7.4), and treated with sodium borohydride (1% in PBS) for 20 minutes.

For Western immunoblots, brain tissue from one monkey and two rats was used. The monkey was overdosed with pentobarbital (100 mg/kg, i.v.), followed by rapid removal of the brain from the skull and dissection. The rodents were rapidly decapitated, and the brain was removed from the skull and dissected on ice.

**Primary antibodies**

**GABA<sub>R</sub> receptor antibodies.** Two polyclonal antibodies against GABA<sub>R</sub> receptors were used in this study. A polyclonal rabbit anti-GAB<sub>R1</sub>B was generated against the intracellular carboxy-terminal domain of the GABA<sub>R1</sub>R1 common to the two splice variants GABA<sub>R1</sub>R1a and GABA<sub>R1</sub>R1b. This polyclonal antibody was generated and biochemically characterized previously by Charara et al. (2000). For this antibody, the sequence of the peptide used for immunization was NH₂-RGPSEPPDRSLCDGSRVHLKY-COOH. An N-terminal lysine was added to the peptide to facilitate coupling to the carrier protein. The specificity of the antibodies was evaluated by immunoblotting of monkey brain and liver membranes (100 μg). Western blot analysis for GABA<sub>R1</sub>R1 revealed that this antiserum selectively recognizes proteins with ~130 kDa and ~100 kDa molecular weights, corresponding, respectively, to the molecular weights of the two splice variants.
GABA<sub>B</sub> receptors in the monkey thalamus

GABA<sub>B</sub>R1a and GABA<sub>B</sub>R1b (Kaupman et al., 1998) in the monkey brain. No band was seen for liver membrane proteins. Immunoreactivity was completely abolished when antibodies were preadsorbed with the synthetic GABA<sub>B</sub>R1 peptide (10 μg/ml) prior to immunoblotting, whereas preadsorption of the antibodies with the GABA<sub>B</sub>R2 peptide (Kuner et al., 1999) had no effect on the distribution and intensity of GABA<sub>B</sub>R1 immunostaining (for details see Charara et al., 2000).

The GABA<sub>B</sub>R2 polyclonal guinea pig antiserum (catalog No. AB5905, lot No. 22090813; Chemicon, Temecula, CA) was raised against a synthetic peptide corresponding to the C-terminal amino acids of the rat and human GABA<sub>B</sub>R2 receptor protein, which is not present in the GABA<sub>B</sub>R1 protein (Kaupman et al., 1998; White et al., 1998; Jones et al., 1998; Martin et al., 1999). Western blot analysis with membranes prepared from cell lines expressing GABA<sub>B</sub>R2 or human and rat brain tissue revealed a single band labeling at approximately 120 kDa (Waldvogel et al., 2004) that corresponds to the molecular weight of GABA<sub>B</sub>R2 (Kaupman et al., 1998; White et al., 1998; Jones et al., 1998; Martin et al., 1999). The specificity of GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 antibodies in monkey brain tissue has been previously shown (Charara et al., 2000, 2004, 2005; Smith et al., 2000, 2001; Gallav et al., 2004).

Vesicular glutamate transporter antibodies. Two polyclonal antibodies were used, a commercially available guinea pig polyclonal anti-vGluT1 directed against a 19-amino acid (aa) peptide sequence in the C-terminal region of the rat vGluT1 (catalog No. AB5905, lot No. 22090813; Chemicon) and a new rabbit anti-rat vesicular glutamate transporter 1 (vGluT1) antibody (Mab Technologies, Atlanta, GA).

To generate rabbit anti-vGluT1 antibodies (Mab Technologies), a peptide was generated to the COOH terminus of the rat vGluT1, corresponding to aa 543–560 (C-ATHSTVQPPRPPPVFVRY). This epitope is highly conserved in the mouse vGluT1 sequence and has one site of divergence in the human sequence (underlined above). A cysteine was added to aid in conjugation to the protein carrier keyhole limpet hemocyanin (KLH; Pierce, Rockford, IL). Antiserum was obtained from rabbits (Covance) immunized with the conjugated peptide, and the IgG fraction was recovered by ammonium sulfate precipitation as follows. Serum was first treated with 25% ammonium sulfate to remove any proteins that might precipitate at low ionic concentrations and incubated with stirring over night at 4°C. After a 3,000 g × 30 minutes spin, the supernatant was removed and transferred to a clean tube. Ammonium sulfate was added to a final concentration of 50% saturation. After another overnight incubation at 4°C, the IgG fraction was isolated in the pellet by centrifugation at 3,000 g × 30 minutes. The pellet was resuspended in PBS and dialyzed overnight with three buffer changes.

The specificity of the guinea pig vGluT1 antiserum was assessed by the following observations. 1) The overall pattern of labeling obtained with this antiserum was the same as that generated with the rabbit anti-vGluT1 antiserum. 2) At electron microscopic levels, both antibodies labeled exclusively axon terminals forming asymmetric synapses. 3) vGluT1-labeled terminals with this antiserum are segregated from vGluT2-immunoreactive boutons in different brain regions (Todd et al., 2003; Alvarez et al., 2004). 4) Preadsorption of the antiserum with the rat vGluT1 C-terminal peptide (cATHSTVQPPRPPPVFVRY; 0.2 μg/ml) abolished completely specific immunostaining, whereas incubation with the C-terminal vGluT2 peptide (cAQDAYSYKDRDDYS; 2.0 μg/ml) had no effect on the quality of immunostaining (Raju and Smith, 2005).

Western immunoblots

All brain membrane samples were prepared at 4°C. After dissection, the striatal tissue was completely homogenized with a sonicator in an ice-cold buffer solution (20 mM HEPES, 10 mM EDTA, 2 mM Na<sub>2</sub>VO<sub>4</sub>). The homogenate was centrifuged for 5 minutes at 2,000 rpm to remove tissue debris, and membranes were isolated from the supernatant by subsequent centrifugation for 30 minutes at 14,000 rpm. The resulting pellet was then solubilized in a buffer solution (20 mM HEPES and 0.1 mM EDTA) before total protein concentration was measured by using the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA). The homogenates were then centrifuged for 30 minutes at 14,000 rpm, and the pellet was solubilized in a lysis buffer [10 mM HEPES, 50 mM NaCl, 0.1 mM EDTA, 1 mM benzamidine, 0.1% Triton X-100, 0.1% sodium deoxycholate (SDS), protease inhibitor cocktail (1 tablet per 50 ml; Roche Diagnostics GmbH, Mannheim, Germany)]. The lysates (5–30 μg protein) were then eluted with 1× SDS-PAGE sample buffer. The samples of brain tissue were resolved by SDS-PAGE and subjected to Western blot analysis with anti-vGluT1 (0.2 μg/ml) antibody. Immunoreactive bands were detected with the enhanced chemiluminescence detection system (Pierce) with horse-radish peroxidase-conjugated goat anti-rabbit secondary antibody (1:4,000; Amersham Biosciences, Little Chalfont, United Kingdom).

Localization of GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 immunoreactivity at the light microscopic level

The immunoperoxidase localization of GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 receptor subtypes was performed by using the avidin-biotin complex (ABC) method (Hsu et al., 1981). After blocked of nonspecific sites with 10% normal horse serum (NGS) and 1% bovine serum albumin (BSA) in PBS incubated for 90 minutes at RT, the sections were incubated for 2 days at 4°C in the ABC solution (1:200; Vector, Burlingame, CA), rinsed again in PBS, and finally incubated for 90 minutes at RT in biotinylated goat anti-rabbit antibody. The sections were then washed in PBS and dialyzed overnight with three buffer changes.

The specificity of the rabbit anti-vGluT1 antiserum (Mab Technologies) in monkey tissue was determined by Western immunoblots and light microscopy analysis of striatal tissue, one of the richest vGluT1-containing structures in the brain (see Fig. 1). Results of the preadsorption immunocytochemical data also apply to the thalamus and other brain regions.

The specificity of the guinea pig vGluT1 antiserum was assessed by the following observations. 1) The overall pattern of labeling obtained with this antiserum was the same as that generated with the rabbit anti-vGluT1 antiserum.
Localization of GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 immunoreactivity at the electron microscopic level

For electron microscopic studies, sections were placed in a cryoprotectant solution (PB, 0.05 M, pH 7.4, containing 25% sucrose and 10% glycerol) for 20 minutes, frozen at −80°C for 20 minutes, thawed, and returned to a graded series of cryoprotectant (100%, 70%, 50%, 30%) diluted in PBS. They were then washed in PBS before being processed for immunocytochemistry.

Immunogold labeling. Sections were immersed in PBS with 10% NGS and 1% BSA to block nonspecific sites. Then incubated in the primary antibodies against GABA<sub>B</sub>R1 (dilution 1:200) and GABA<sub>B</sub>R2 (dilution 1:500). They were next processed for the visualization of GABA<sub>B</sub> receptors according to the protocol described above, except that Triton X-100 was not included in the solutions.

Immunoperoxidase labeling. For this protocol, sections were preincubated in PBS containing 5% nonfat dry milk and then washed in Tris-buffered saline (TBS)-gelatin buffer (0.02 M Tris, 0.15 M NaCl, 1 µg/ml fish gelatin, pH 7.6) to block the nonspecific sites. Primary and secondary antibodies were diluted in TBS-gelatin buffer containing 1% nonfat dry milk. The dilutions of GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 antibodies were the same as those used for immunoperoxidase. After incubation in the primary antibodies (48 hours, 4°C), sections were rinsed in TBS-gelatin and incubated for 2 hours at RT in the appropriate gold-conjugated secondary IgGs (dilution 1:100; Nanogold; Nanoprobes Inc.), and gold particles (1.4 nm) were silver enhanced with the HQ Silver kit (Nanoprobes Inc.). As controls for the specificity of the immunolabeling, omission of the primary antibodies from incubation solutions completely abolished the immunostaining for the corresponding antigens.

Double immunolabeling. For double immunolabeling, sections were incubated overnight at RT with a cocktail of rabbit anti-GABA<sub>B</sub>R1 antibodies (dilution 1:200) and guinea pig anti-vGluT1 antibodies (dilution 1:5,000; Chemicon) or with guinea pig anti-GABA<sub>B</sub>R2 antibodies plus rabbit anti-vGluT1 antibodies (dilution 1:5,000; MAB Technologies). For this reaction, all antibodies were diluted in TBS-gelatin solution with 1% nonfat dry milk. After rinses with TBS-gelatin, the sections were incubated for 2 hours at RT with goat anti-rabbit IgGs conjugated with 1.4-nm gold particles (1:100; Nanoprobes Inc.) and biotinylated goat anti-guinea pig antibodies (1:200 dilution; Vector) or with goat anti-guinea pig IgGs conjugated with 1.4-nm gold particles (1:200 dilution; Vector) and biontynlated goat anti-rabbit IgGs (1:200 dilution; Vector). After washes with TBS-gelatin, sections were incubated for 90 minutes at RT in an ABC solution (1:100; Vector). Sections were rinsed with TBS-gelatin and then transferred to a 1% aqueous sodium acetate solution before the silver intensification of the gold particles with HQ silver kit (Nanoprobes Inc.) for 5–6 minutes. The silver reaction was stopped in sodium acetate, and sections were washed in PBS and Tris buffer (0.005 M, pH 7.6) before being processed with DAB as described above. Sections were then processed for electron microscopy.

A series of control sections was incubated with primary antibodies against GABA<sub>B</sub>R1 or GABA<sub>B</sub>R2 with vGluT1. This was followed by incubation in biotinylated secondary antibodies and ABC. Then, sections were processed for silver intensification and the DAB reaction. In both cases, only immunoperoxidase-positive boutons were detected. On the contrary, when the biotinylated secondary antibodies were omitted and the tissue was processed only with secondary gold-conjugated antibodies, single immunogold labeling for GABA<sub>B</sub>R1 or GABA<sub>B</sub>R2 was visualized.

A second series of control sections was incubated with both secondary antibodies and processes for immunoperoxidase or immunogold methods as described above, but the primary antibodies for either GABA<sub>B</sub> receptor subtypes or vGluT1 were omitted in turn from the incubation solutions. These reactions led to peroxidase labeling for vGluT1 only following omission of the GABA<sub>B</sub> receptor antibodies, whereas only the gold particle labeling for either GABA<sub>B</sub> receptor subtypes could be seen in sections processed without the vGluT1 antibodies.

Processing for electron microscopy

After immunostaining, sections were washed in PB (0.1 M, pH 7.4) and postfixed in osmium tetroxide (1–0.5% in PB). This was followed by rinses in PB (0.1 M, pH 7.4) and dehydration in a graded series of ethanol and propylene oxide. Uranyl acetate (1%) was added to the 70% ethanol to improve the contrast in the electron microscope. The sections were then embedded in resin (Durcupan ACM; Fluka, Fort Washington, PA), mounted on microscope slides, and placed in the oven for 48 hours at 60°C. Areas of interest were selected, cut from the slides, and glued on top of resin blocks. In some cases, areas of interest were photographed in the light microscope before being cut out and glued on blocks. From these blocks, correlated semithin sections (~1 µm) were obtained on the ultramicrotome (Leica Ultracut T2), and counterstained with 0.1% toluidine blue (see Fig. 2A,B).

The CM and PF nuclei were identified in the resin-embedded sections as follows. Serial adjacent sections of monkey thalamus were either processed for electron microscopy or Nissl stained with cresyl violet. Although the nuclear outlines are not clear in the osmicated section, the Nissl-stained serial section was used as a reference to differentiate PF from CM. In Nissl-stained material, both nuclei are easily differentiated; the PF is identified as the medially most region of the complex that contains densely packed, small, round perikarya, which can be easily differentiated from the CM, located more laterally with a lower density of cells, which appear paler in Nissl-stained material (for further details see Sidibe et. al., 2002).

Serial ultrathin sections were obtained on the ultramicrotome (Leica Ultracut T2), collected onto Pioloform-coated single-slot copper grids, stained with lead citrate (Reynolds, 1963), and examined with the electron microscope (Zeiss EM 10C). The electron micrographs were acquired with a CCD camera (DualView 300W; Gatan, Pleasanton, CA) controlled by DigitalMicrograph software (version 3.8.1; Gatan).
Photomicrograph production

Some digitally acquired micrographs were adjusted only for brightness and contrast, while maintaining the pixel dimension contrast, with either DigitalMicrograph or Photoshop 7.0 (Adobe System, Inc., San Jose, CA) to optimize the quality of the images for analysis.

Analysis of the material

For quantitative measurements of the relative abundance of the different immunoreactive elements for each receptor subtype in CM/PF, only those monkeys with the best ultrastructural preservation were used. For the peroxidase analysis, the animals were MR73 and MR75 for GABA<sub>B</sub>R1 and MR72 and MR74 for GABA<sub>B</sub>R2. For the preembedding immunogold analysis, the animals were MR75 and MR87 for GABA<sub>B</sub>R1 and MR75 and MR100 for GABA<sub>B</sub>R2.

Taking into consideration the limited access of antibodies to antigenic sites deep in the sections, and to minimize false negatives, electron microscopic ultrathin sections were obtained from the surface of each block, and areas with optimal immunolabeling and good ultrastructural preservation were photographed. Furthermore, considering that GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 antibodies may display different degrees of sensitivity for their antigenic sites, we compared the distribution of GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 labeling based on the relative percentages of immunoreactive elements for either receptor subtype. By using this approach, we avoid misinterpretation of false-negative labeling resulting from technical issues, because the ground truth of immunolabeling and good ultrastructural preservation were photographed. A similar approach was used previously in our laboratory to quantify GABA<sub>B</sub> receptors in other nuclei (Charara et al., 2001; Kuwajima et al., 2004) or other receptor subtypes throughout the basal ganglia (Hanson and Smith, 1999; Hubert et al., 2001; Kuwajima et al., 2004).

Immunoperoxidase labeling. Ultrathin sections from the most superficial sections of blocks were scanned at ×20,000, and all immunoreactive elements randomly encountered were photographed. The total surface of tissue analyzed for GABA<sub>B</sub>R1 in CM and PF was 2,567 μm<sup>2</sup> and 5,890 μm<sup>2</sup>, respectively, and, for GABA<sub>B</sub>R2, 2,898 μm<sup>2</sup> of CM tissue and 5,969 μm<sup>2</sup> of PF were examined. The total number of blocks of tissue/animal analyzed was, for GABA<sub>B</sub>R1, CM: two blocks/monkey MR73 and two blocks/monkey MR75; PF: one block/monkey MR73 and three blocks/monkey MR75; and, for GABA<sub>B</sub>R2, CM and PF: two blocks/monkey MR72 and two blocks/monkey MR74.

The labeled elements were categorized as somatic profiles, dendrites, vesicle-containing dendrites, axon-like processes, and axon terminals based on ultrastructural criteria defined by Peters et al. (1991). Although the presence of DAB deposit complicated the identification of small-diameter processes, these were categorized as axon-like processes based on their small diameter (<0.3 μm), absence of mitochondria, lack of synaptic input, and occasional presence of neurofilaments and synaptic vesicles. The relative proportion of each element was calculated and expressed as a percentage of total number of labeled elements for each receptor subtype in each nucleus. Statistical differences in the pattern of distribution of the two GABA<sub>B</sub> receptor subunits were assessed with nonparametric chi-square analysis (StatView 5.0).

Preembedding immunogold labeling. Ultrathin sections from the surface of the blocks were examined under the electron microscope, and elements containing gold particles were photographed at ×20,000–31,500. The immunogold particles for GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 were counted and categorized as intracellular or bound to the plasma membrane. To determine the location of GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 relative to synapses, the membrane-associated gold particles were categorized as 1) synaptic, when they were in the main body of symmetric or asymmetric synaptic specialization (pre- or postsynaptic); 2) perisynaptic, when they were at the edges of symmetric or asymmetric synaptic specializations; 3) extrasynaptic; postsynaptic, when they were laying along the nonsynaptic portion of the plasma membrane; and 4) extrasynaptic; presynaptic, when they were associated with nonsynaptic membrane or the intracellular compartment of the terminal. To avoid misinterpretations resulting from nonspecific light background labeling, immunoreactive elements had to contain a minimum of three gold particles to be considered in this analysis. The results for quantification were expressed as relative percentages of total gold particle labeling, and nonparametric chi-square analysis (StatView 5) was used to compare the distribution of the two GABA<sub>B</sub> receptor subunits.

Double immunolabeling. For double labeling, data were collected in the same way as previously described, but in this case only immunogold-labeled elements making synaptic contact with immunoperoxidase-labeled boutons were photographed. To avoid false-negative labeling from the poor penetration of gold particles, analysis was restricted to the most superficial sections where both the peroxidase- and the gold-conjugated antibodies had access to their antigenic sites.

RESULTS

Immunoblotting

Antibody specificity was examined by using Western blot analysis and preadsorption tests on monkey and rat striatal tissue for a recently generated antibody against vGluT1 (Mab Technologies). Immunoblot analysis of monkey and rat striatal tissue showed that the anti-vGluT1 antibody recognized a single band at the molecular weight predicted for vGluT1 (~60 kDa; Fig. 1A). Immunoperoxidase staining of monkey and rat (data not shown) striatal tissue showed immunoreactivity in the neuropil (Fig. 1B), as previously reported for rat striatum (Fremeau et al., 2001; Herzog et al., 2001; Varoqui et al., 2002). Furthermore, this immunoreactivity was abolished when the anti-vGluT1 antibody was preadsorbed with the synthetic peptide of antigenic sequence against which it was generated (Fig. 1C). However, the immunoreactivity was maintained when the anti-vGluT1 antibody was preadsorbed with the synthetic peptide for vesicular glutamate transporter 2 (vGluT2; Fig. 1D). The tissue was devoid of immunoreactivity when the primary antibodies were omitted from the incubation solution (Fig. 1E).

At the ultrastructural level, the anti-vGluT1 antibodies labeled exclusively axon terminals forming asymmetric synapses mostly with dendritic spines and distal axons containing synaptic vesicles (Raju and Smith, 2005), as previously reported in the rat striatum using other specific vGluT1 antisera (Fremeau et al., 2001; Herzog et al., 2001; Varoqui et al., 2002).
General distribution of GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 in the CM/PF complex

At the light microscopic level, moderate to strong immunostaining for GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 was found throughout the monkey thalamus. Overall, dorsal thalamic nuclei showed a higher level of immunostaining than ventral thalamic nuclei, except for the intralaminar complex, in which the labeling for both receptor subtypes was intense but lower than in the surrounding nuclei, including the mediodorsal, periventricular, pulvinar, and ventroposterior. This pattern of immunostaining is consistent with the expression of GABA<sub>B</sub> receptor gene transcripts (Muñoz et al., 1998) and GABA<sub>B</sub> receptor binding sites (Bowery et al., 1999) in the monkey thalamus.

A similar pattern of immunoreactivity was found for GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 in CM/PF in DAB-stained (Fig. 2A,B) or gold-stained (Fig. 2C,D) sections. In DAB-processed material, strong immunoreactivity was observed in both large and small cell bodies and primary dendrites (Fig. 2A,B). The DAB reaction product was diffusely distributed but also formed small aggregates within the cytoplasm of labeled neurons (Fig. 2B). In general, perikarya and proximal dendrites displayed a lighter level of immunoreactivity in tissue sections processed for immunogold, but abundant immunoreactive processes and punctuate elements for both subunits formed a dense neuropil meshwork in both nuclei (Fig. 2C,D).

Subcellular localization of GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 in CM/PF

To study the overall cellular and subcellular distribution of the GABA<sub>B</sub> receptor subunits in CM/PF, we used the ABC electron microscopy immunoperoxidase method. In the electron microscope, the DAB-labeled antigenic sites were recognized by the presence of amorphous electron-dense deposit (Figs. 3, 4A–C). Immunoreactivity for GABA<sub>B</sub>R1 (Figs. 3A–C, 4A) and GABA<sub>B</sub>R2 (Fig. 3D–F, 4B,C) was observed predominantly in dendritic processes (Fig. 3A,B,D,E), although small, unmyelinated, axon-like processes (Fig. 3A,B,D,E) and rare axon terminals (Fig. 3C,F) were also immunolabeled in CM and PF nuclei.

In both nuclei, neuronal soma of large projection neurons (PN) or small local circuit neurons (LCN) were immunoreactive for GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 (Fig. 4A,B). In general, the immunoperoxidase deposit was diffusely distributed into the labeled cell bodies, with occasional intense patches of staining mainly associated with the rough endoplasmic reticulum (see immunogold data in Fig. 6). In labeled dendrites of PN, the immunoperoxidase deposit was associated mainly with microtubules (Fig. 3A,B,D,E), whereas, in vesicle-containing dendrites (vcd) of LCN and axon terminals, the labeling was often associated with the external surface of synaptic vesicles (Figs. 3C,F, 4C).

To assess further the proportion of LCN dendrites expressing GABA<sub>B</sub>R1 or GABA<sub>B</sub>R2, labeled and unlabeled vesicle-containing dendrites (vcd) for either receptor subtypes were counted in sections of CM/PF. This series of experiments revealed that 17% and 15% of LC dendrites were immunoreactive for GABA<sub>B</sub>R1 in CM/PF, respectively, whereas 15% and 14% were labeled for GABA<sub>B</sub>R2 in these nuclei (Fig. 4D).

Because GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 form functional heterodimers, one would expect these two receptor subtypes to display a similar pattern of subcellular distribution. For both subunits in both thalamic nuclei, almost 80% of the total labeling was found in dendrites, and the remaining labeled elements were accounted for by small, unmyelinated, axon-like processes (CM: 19% and 20% for GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2, respectively). Less than 5% of labeling was found in axon terminals, and less than 1% was associated with LCN dendrites (Fig. 5). No significant differences were found in the pattern of GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 labeling in CM and PF, except for the percentage of GABA<sub>B</sub>R2-immunoreactive terminals in PF, which was significantly higher than for GABA<sub>B</sub>R1 (chi-square analysis, P < 0.01; Fig. 5B).

Subsynaptic localization of GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2

The detailed subcellular and subsynaptic localization of GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 in the caudal intralaminar thalamic nuclei was studied by using the preembedding immunogold method at the electron microscopic level. Although this method is less sensitive than the immunoperoxidase technique, the main advantage of the
immunogold method is the higher level of spatial resolution of the gold particles compared with the diffusible DAB reaction product, allowing a more accurate assessment of the spatial localization of GABA<sub>B</sub> receptor sites. Despite the technical limitation inherent to the sensitivity of the preembedding immunogold technique to assess the extent of synaptic labeling, this method provides a detailed map of extrasynaptic and perisynaptic GABA<sub>B</sub> receptors. Additional postembedding labeling will be necessary to confirm the precise extent of GABA<sub>B</sub> synaptic receptors (Figs. 6, 7). However, it is noteworthy that a previous study that used pre- and postembedding methods to examine GABA<sub>B</sub>R1/R2 distribution in the rat thalamus did not report major differences between the degree of synaptic labeling generated with these two immunogold methods (Kulik et al., 2002).

Consistently with the peroxidase observations, the immunogold method resulted in strong labeling in both thalamic nuclei. The subcellular distribution of GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 immunogold labeling in CM and PF was determined by counting the number of intracellular and plasma membrane-bound gold particles as described in Materials and Methods.
Fig. 3. Electron micrographs showing immunoperoxidase staining for GABA\_R1 and GABA\_R2 in CM and PF. A–C: GABA\_R1 immunostaining in CM (A,C) and PF (B). D–F: GABA\_R2 immunostaining in CM (D,F) and PF (E). A,B: GABA\_R1 immunostaining is found mainly in dendrites (den) and small axon-like processes (ax) in CM and PF. C: A GABA\_R1-immunolabeled axon terminal (at) forming an axodendritic asymmetric synapse (arrowhead) with a nonimmunoreactive dendrite in CM. D,E: A similar pattern of immunostaining is found for GABA\_R2 in CM and PF, with abundant labeling in dendrites (den) and axon-like processes (ax). F: A GABA\_R2-immunoreactive axon terminal (at) forming an asymmetric synapse (arrowhead) with an immunolabeled dendrite (den) in CM. Note the peroxidase labeling associated mainly with microtubules in GABA\_R1- and GABA\_R2-immunostained dendrites (arrows). Scale bars = 0.5 μm.
GABA<sub>B</sub> receptors in the monkey thalamus

GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 immunolabeling was observed in the soma of both PN and LCN in CM and PF (Fig. 6). For both subunits, and in both cell types, quantitative analysis showed that under 20% of the immunogold particles were bound to the plasma membrane (Fig. 6D). The majority of labeling (>80%) was located in the cytoplasm (Fig. 6A,A',D), where it was associated mainly with the membranes of the rough endoplasmic reticulum (Fig. 6A'). Plasma membrane-bound cell body labeling for GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 in PN and LCN was all extrasynaptic in both nuclei. In some instances, GABA<sub>B</sub>R1 receptor labeling was associated with close appositions between immunoreactive cell bodies and LCN dendrites or large axon terminals (Fig. 6B,C).

Immunolabeling for both GABA<sub>B</sub> receptor subunits was also strongly expressed in dendrites of PN in CM and PF (Fig. 7A–D). For GABA<sub>B</sub>R1, most gold particles (69% in CM and 78% in PF) were associated with the plasma membrane, whereas, for GABA<sub>B</sub>R2, the proportion of gold particles bound to the plasma membrane (55% in CM and 60% in PF) was only slightly higher than the proportion of intracellular labeling (Fig. 7E). These intracellular gold
particles were associated with vesicular organelles or bound to the smooth endoplasmic reticulum and microtubules (Fig. 7A–D). Statistical analysis (chi-square) showed that the intracellular labeling for GABABR2 was significantly higher than for GABABR1 in both CM and PF (Chi-square: 87.7, \( P < 0.0001 \) in CM; 53.9, *, \( P < 0.0001 \) in PF; Fig. 7E).

The comparative analysis of the distribution of synaptic and extrasynaptic immunogold particles for GABABR1 and GABABR2 in dendritic profiles in CM and PF (Fig. 7F) showed that the plasma membrane immunolabeling for both subunits was found mainly at extrasynaptic sites (93% for GABABR1 and GABABR2 in CM, 92.5% for GABABR1 and 98% for GABABR2 in PF). Immunogold particles labeling for GABABR1 associated with synapses (7.5%) was significantly higher than for GABABR2 (2%) synaptic labeling in PF (chi-square: 16.67, *, \( P < 0.0001 \)).

Quantitative analysis of immunogold particles located at synaptic sites revealed that GABABR1 and GABABR2 immunolabeling was found in the main body or at the edges of symmetric synapses (Fig. 8A). Although there was no difference in the overall pattern of distribution between the two receptor subunits at symmetric synapses in CM, the proportion of synaptic labeling for GABABR1 and GABABR2 was twice more common than the level of perisynaptic labeling in PF (Fig. 8A).

Extrasynaptic labeling for GABABR1 and GABABR2 (Fig. 8B) was observed in axon terminals forming either symmetric or asymmetric synapses with dendritic shafts in CM and PF. In both thalamic nuclei, presynaptic immunogold particles labeling for GABABR1 (67% in CM and 73% in PF) and GABABR2 (71% in CM and PF) were mainly intracellular or extrasynaptic. It was located inside the terminal or associated with nonsynaptic sites along the terminal plasma membrane (Fig. 7C,D). Only \( \sim 10 – 20\% \) of the presynaptic labeling was associated with the active zone of symmetric and asymmetric synapses (Figs. 7B, 8B). In both types of synapses, immunogold particles were found in the core or at the edge of presynaptic specializations (Figs. 7B–D, 8B).

To characterize further the neurotransmitter content of terminals associated with GABAB receptors labeling, we used a double immunocytochemical approach to localize GABABR1/R2 labeling with vGluT1 immunoreactivity. In this material, vGluT1 immunolabeling was localized with DAB, whereas GABABR1/GABABR2 immunoreactivities were detected with immunogold (Fig. 9). Results of these experiments confirm and extend our single-labeling data showing that postsynaptic GABABR1/GABABR2 immunoreactivity is expressed at the edges of asymmetric synapses formed by vGluT1-containing terminals in the CM/PF complex (Fig. 9A,C,D). Gold particles were never seen in the core of asymmetric synapses. Although much less frequently encountered, presynaptic immunoreactivity for GABABR1 or GABABR2 was expressed in vGluT1-labeled terminals, either extrasynaptically or in the active zones (Fig. 9B).

The present study provides the first description of the subcellular and subsynaptic distribution of GABABR1 and GABABR2 in the monkey caudal intralaminar nuclear complex. The following conclusions can be drawn from our observations. 1) There is no major difference in the pattern of subcellular and subsynaptic distribution of either GABAB receptor subunit between CM and PF. 2) Both subunits are heavily expressed postsynaptically and largely confined to dendrites and axon-like processes but are rarely found in axon terminals. 3) About 20% of vesicle-containing dendrites of LCN neurons express GABABR1 and GABABR2 immunoreactivity in both nuclei. 4) Postsynaptic GABAB receptors are largely associated with extrasynaptic and perisynaptic sites at symmetric and asymmetric axodendritic and axosomatic synapses. 5) There is a significant difference in the pattern of subcellular distribution of GABABR1 and GABABR2 in CM and PF. Seventy to eighty percent of GABABR1 labeling is found on the plasma membrane, whereas GABABR2 immunoreactivity is more evenly distributed between the

**DISCUSSION**

To characterize further the neurotransmitter content of terminals associated with GABAB receptors labeling, we used a double immunocytochemical approach to localize GABABR1/R2 labeling with vGluT1 immunoreactivity. In this material, vGluT1 immunolabeling was localized with DAB, whereas GABABR1/GABABR2 immunoreactivities were detected with immunogold (Fig. 9). Results of these experiments confirm and extend our single-labeling data showing that postsynaptic GABABR1/GABABR2 immunoreactivity is expressed at the edges of asymmetric synapses formed by vGluT1-containing terminals in the CM/PF complex (Fig. 9A,C,D). Gold particles were never seen in the core of asymmetric synapses. Although much less frequently encountered, presynaptic immunoreactivity for GABABR1 or GABABR2 was expressed in vGluT1-labeled terminals, either extrasynaptically or in the active zones (Fig. 9B).
plasma membrane and the intracellular compartment. Some of the GABA \(_{\text{B}}\)R1- and GABA \(_{\text{B}}\)R2-containing terminal boutons forming asymmetric synapses express vGluT1 immunoreactivity. These findings provide a solid framework whereby GABA \(_{\text{B}}\) receptors could be involved in regulating extrinsic and intrinsic GABAergic and glutamatergic inputs to the CM/PF complex in primates.

**Subcellular localization of GABA \(_{\text{B}}\) receptors in CM/PF**

Intense postsynaptic immunolabeling for GABA \(_{\text{B}}\)R1 and GABA \(_{\text{B}}\)R2 was found in CM/PF, being mostly associated with dendritic elements. It is important to note that the pattern of subcellular distribution of GABA \(_{\text{B}}\)R1 and GABA \(_{\text{B}}\)R2 varies substantially between brain regions. For instance, the pattern of labeling in the rat ventrobasal thalamic nucleus, cerebellum, and hippocampus (Kulik et al., 2002, 2003; López-Bendito et al., 2004) resembles that described here for CM/PF, i.e., dendritic immunolabeling for either GABA \(_{\text{B}}\) receptor subunits being mostly associated with the plasma membrane. On the other hand, GABA \(_{\text{B}}\)R1 subunit labeling is largely expressed intracellularly in various basal ganglia nuclei in rats and monkeys (Smith et al., 2000, 2001; Boyes and Bolam, 2003;
Fig. 7. Ultrastructural localization of immunogold labeling for GABA_B1 and GABA_B2 in CM and PF. A: Labeling for GABA_B1 is found in numerous dendrites (den) in CM. Gold particles are associated mainly with the internal surface of the plasma membrane (single arrows) but are also found in intracellular sites (double arrows). B: Postsynaptic labeling for GABA_B1 in PF. In the dendrite (den), gold particles are mainly attached to extrasynaptic sites (arrows) along the plasma membrane. Note also a gold particle at the edge of the postsynaptic density (arrowhead). C,D: Immunogold labeling for GABA_B2 in CM. Immunogold particles are present mostly along extrasynaptic sites on the dendritic plasma membrane (single arrows in C and D) and occasionally at the edge of asymmetric synapses (single arrowheads in den₁ and den₂). Note the presence of numerous intracellular gold particles (double arrows in den₁ and den₂). Some immunogold particles are observed on the presynaptic membrane (double arrowheads in at₁ and at₂) or intracellularly (at₃ and at₄) in axon terminals forming asymmetric synapses. Note also a gold particle associated with a puncta adherens-like contact (pa) between den₃ and den₄ in D. E,F: Histograms showing the relative proportion and distribution of GABA_B1 and GABA_B2 immunogold particles labeling in CM and PF. E: Plasma membrane-bound immunogold particles vs. intracellular labeling. The percentage of GABA_B1 immunogold labeling associated with the plasma membrane is significantly higher than the proportion of plasma membrane-bound GABA_B2 labeling (chi-square analysis, *, P < 0.0001). F: Comparative distribution of synaptic and extrasynaptic immunogold particles for GABA_B1 and GABA_B2. For both receptor subunits, immunolabeling was found mainly extrasynaptically (90–95%). Statistical analysis demonstrated that the proportion of synaptic GABA_B1 immunogold particles was significantly higher than for GABA_B2 in PF (*, P < 0.0001). The number of gold particles/dendrites sampled in CM and PF was 2,501/315 for GABA_B1 in CM, 617/100 for GABA_B1 in PF, 1,829/230 for GABA_B2 in CM, and 887/110 for GABA_B2 in PF. Scale bars = 0.5 μm.
Fig. 8. Subsynaptic distribution of postsynaptic (A) and presynaptic (B) immunogold particles labeling for GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 in CM and PF. A: Relative distribution of immunogold particles associated with the postsynaptic plasma membrane of symmetric (sym) and asymmetric (asym) synapses. One hundred percent is the total number of gold particles associated with synaptic sites on the plasma membrane. B: Relative distribution of presynaptic GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 immunogold particles located in axon terminals that form symmetric and asymmetric synapses in CM and PF. One hundred percent is the total number of gold particles in the immunolabeled axon terminals. Each gold particle is categorized as extrasynaptic (Extrasyn), synaptic (Syn), or perisynaptic (Peri). Total number of gold particles/elements sampled postsynaptic in CM: 16/70 dendrites for GABA<sub>B</sub>R1 and 15/4/70 dendrites for GABA<sub>B</sub>R2; postsynaptic in PF: 36/25 for GABA<sub>B</sub>R1 and 38/20 for GABA<sub>B</sub>R2; presynaptic in CM: 15/35 terminals for GABA<sub>B</sub>R1 and 150/36 terminals for GABA<sub>B</sub>R2; presynaptic in PF: 70/25 terminals for GABA<sub>B</sub>R1 and 62/20 terminals for GABA<sub>B</sub>R2.

Chen et al., 2004; Galvan et al., 2004; Charara et al., 2005, suggesting the possibility of different trafficking and synaptic targeting mechanisms to regulate GABA<sub>B</sub> receptor plasma membrane expression and functions in different brain regions.

In a functional GABA<sub>B</sub> receptor, GABA<sub>B</sub>R1 is the subunit responsible for the binding of GABA, and GABA<sub>B</sub>R2 is required to bring GABA<sub>B</sub>R1 to the cell surface (White et al., 1998; Kaupmann et al., 1998; Kuner et al., 1999). It is believed that association of GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 is necessary to form functional GABA<sub>B</sub> receptors (Jones et al., 1998; Kaupmann et al., 1998; White et al., 1998; Benke et al., 1999; Kuner et al., 1999; Bowery and Enna, 2000; Calver et al., 2001; Bowery et al., 2002; Bettler et al., 2004; Cryan and Kaupmann, 2005). When expressed alone, GABA<sub>B</sub>R1 is retained in the endoplasmic reticulum as a quality-control mechanism preventing incorrectly folded GABA<sub>B</sub> receptors from reaching the cell surface (Couve et al., 1998; Bettler et al., 2004). Expression of GABA<sub>B</sub>R1 on the cell surface or its retention in the cytoplasm is an obvious regulatory mechanism of GABAergic neurotransmission. Taking into account that the GABA<sub>B</sub>R2 subunit is also necessary for proper G-protein signaling in response to agonist stimulation (Couve et al., 2000; Jones et al., 2000; Calver et al., 2001; Margeta-Mitrovic et al., 2001a; Robbins et al., 2001; Bettler et al., 2004; Pin et al., 2004), a similar pattern of subcellular plasma membrane expression for both subunits would be expected. Therefore, the significant differences between the intracellular and the plasma membrane expression of GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 subunits that were found in the monkey CM/PF complex suggest that some of the plasma membrane immunolabeling for GABA<sub>B</sub>R1 likely corresponds to nonfunctional GABA<sub>B</sub> receptors, in that GABA<sub>B</sub>R1 is incapable of G-protein activation (Pin et al., 2004). Another possibility is that GABA<sub>B</sub> receptor trafficking to the plasma membrane occurs by heterooligomerization of GABA<sub>B</sub>R1 subunit with other receptor subunits, such as the GABA<sub>A</sub> receptor γ2, as recently shown in vitro (Balasubramanian et al., 2004), or other GABA<sub>A</sub> subunits that have not yet been identified. It is interesting to note that a new positive allosteric regulator of the GABA<sub>B</sub>R2 subunit, CGP7930, has recently been described (Binet et al., 2004; Pin et al., 2004), opening up new possibilities for therapeutic regulation and/or activation of GABA<sub>B</sub> receptors under pathological conditions. It is noteworthy that correlation between GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 distributions is a common, but not a general, phenomenon in the CNS (Charara et al., 2000, 2004; Clark et al., 2000; Ng and Yung, 2001), suggesting that other molecular mechanisms and/or additional GABA<sub>B</sub> receptor subunits may be involved in the formation of native GABA<sub>B</sub> receptors in some brain regions (Kaupmann et al., 1998; Durkin et al., 1999; Calver et al., 2000, 2003; Mezler et al., 2001; Charara et al., 2004).

**GABA<sub>B</sub> receptor are expressed mostly at extrasynaptic sites**

The immunogold labeling for GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2 was found mainly at extrasynaptic sites in dendrites and axon terminals, a pattern of distribution reminiscent of that described in other brain regions, including the rat ventrobasal thalamus (Fritschy et al., 1999; Smith et al., 2000, 2001; Kulik et al., 2002; Boyes and Bolam, 2003; Chen et al., 2004; Galvan et al., 2004; Charara et al., 2005). This extrasynaptic localization of GABA<sub>B</sub> receptors is consistent with electrophysiological data showing that prolonged and high-frequency burst discharge of inhibitory neurons are required to activate GABA<sub>B</sub> receptors (Mody et al., 1994; Kim et al., 1997), indicating a neurotransmitter role for these receptors. If most of the GABA<sub>B</sub> receptor effects occur at extrasynaptic sites, this raises various issues regarding the sources of GABA and regulatory mechanisms of these receptors activation. Considering the high sensitivity of GABA<sub>B</sub> receptors to GABA (Sodickson and Bean, 1996), spillover and extrasynaptic diffusion of GABA from adjacent GABAergic synapses have been suggested as mechanisms by which extrasynaptic receptors are activated (Atwell et al., 1993; Vogt and Nicoll, 1999; Scanziani, 2000). Consistently with this hypothesis, a recent in vivo analysis demonstrated that local application of GABA transporter (GAT) blockers increases...
GABA-mediated effects and GABA levels in the monkey globus pallidus (GP; Galvan et al., 2005).

Our quantitative analysis showed that ~20% of immunoperoxidase labeling for GABABR1 and GABABR2 was found in small axon-like processes in CM/PF. Axonal localization has also been described for several neurotransmitter receptors (5-HT1B serotonin receptors, A1 adenosine receptors, D1 dopamine receptors, group II mGluRs, GluR6/7, KARs subunits, etc.) in the CNS (Swanson et al., 1995, 1998; Yung et al., 1995; Lujañ et al., 1997; Charara et al., 1999; Riad et al., 2000; Tamaru et al., 2001; Kane-Jackson and Smith, 2003; Poisik et al., 2005). The fact that immunolabeling for GABAB subunits in axon terminals was rather scarce in CM/PF suggests that GABAB receptors in terminals have a fast turnover and that axonal labeling represents receptor subunits traveling to the axon terminal. Another possibility is that axonal GABAB receptors are functional receptors that modulate axonal conduction and presynaptically regulate neurotransmitter release, as shown for other G protein-coupled receptor subtypes (Radnikow and Misgeld, 1998; Swanson et al., 1998; Bradley et al., 2000; Capogna, 2004; Poisik et al., 2005).

Although the exact mechanisms of activation of these axonal receptors remain poorly understood, they likely rely on neurotransmitter spillover in the extracellular space, insofar as axoaxonic synapses are rarely seen in brain regions endowed with axonal receptors. It is noteworthy that other presynaptic receptors are tightly linked with the presynaptic plasma membrane of terminals close to the site of release of neurotransmitter (Shigemoto et al., 1997; Bradley et al., 2000). These observations, therefore, suggest that the exact location of presynaptic receptors might be a critical factor that sets their physiological characteristics and modulatory functions of neurotransmission in the CNS. To understand better the significance of GABAB receptor axonal labeling in the thalamus, the sources of immunoreactive axons must be determined.

**Synaptic expression of GABAB receptors in CM/PF**

Electrophysiological evidence indicates that GABAB receptors might act as pre- or postsynaptic receptors in the thalamus (Banerjee and Sead, 1995; Pape and McCormick, 1995; Williams et al., 1996; Soltesz and Crunelli, 2000).
GABA<sub>B</sub> RECEPTORS IN THE MONKEY THALAMUS

I mGluRs and the GABA<sub>B</sub> receptor distribution through-out the CNS (Smith et al., 2000, 2001; Marino et al., 2001; Smith et al., 2001; Galvan et al., 2004, 2005). This obvious difference in the localization for GABA<sub>B</sub> receptors has been described in the ventrobasal thalamic nucleus (Kulik et al., 2002; Charara et al., 2002; Boyes and Bolam, 2003; Chen et al., 2004; Galvan et al., 2004; Charara et al., 2005).

A small subset of GABA<sub>B</sub> receptors was found in the main body or at the edges of symmetric, putative GABAergic, synapses in the monkey CM/PF. A similar postsynaptic localization for GABA<sub>B</sub> receptors has been described in the rat ventrobasal thalamic nucleus (Kulik et al., 2002) and various basal ganglia nuclei in both rats and monkeys (Fritschy et al., 1999; Smith et al., 2000, 2001; Gonchar et al., 2001; Kulik et al., 2002, 2003; Boyes and Bolam, 2003; Chen et al., 2004; Galvan et al., 2004; Charara et al., 2005).

This rather scarce synaptic labeling of GABAergic synapses is strikingly different from GABA<sub>A</sub> receptor sub-units, which are almost exclusively expressed in the core of GABAergic synapses in some brain regions (Somogyi et al., 1996; Kultas-Ilinsky et al., 1998; Galvan et al., 2004; Charara et al., 2005). This obvious difference in the localization of the two main subtypes of GABA receptors provides further support for complex and heterogeneous mechanisms whereby GABAergic transmission could be mediated in the CNS.

In addition, postsynaptic GABA<sub>B</sub> receptors were found at the edges of asymmetric synapses (putative excitatory) in CM/PF, a pattern described in different areas of the CNS (Fritschy et al., 1999; Gonchar et al., 2001; Kulik et al., 2002; Boyes and Bolam, 2003; Chen et al., 2004; Galvan et al., 2004; Luján et al., 2004, 2005; Charara et al., 2005). Some of the glutamatergic synapses endowed with pre- and postsynaptic GABA<sub>B</sub> receptor labeling are formed by vGluT1-containing boutons. Taking into consideration that vGluT1-containing terminals in the thalamus most likely arise from the cerebral cortex (Fremeau et al., 2001, 2004), activation of GABA<sub>B</sub> heteroreceptors in these glutamatergic terminals may regulate transmitter release from corticothalamic afferents. On the other hand, the presence of GABA<sub>B</sub> receptors at the edges of asymmetric synapses formed for vGluT1-positive terminals suggests the possible interaction between GABAergic and metabotropic glutamate receptors (mGluRs) to regulate excitatory synaptic transmission in CM/PF. Such functional interactions between GABA<sub>B</sub> receptors and mGluR1 have been shown in the cerebellum, where excitatory mGluR1-mediated postsynaptic currents were enhanced by activation of postsynaptic GABA<sub>B</sub> receptors (Hirono et al., 2001).

On the basis of the similarity between the pattern of group I mGluRs and the GABA<sub>B</sub> receptor distribution throughout the CNS (Smith et al., 2000, 2001; Marino et al., 2001; Muly et al., 2003), one might expect functional receptor–receptor interactions to be an important mechanism whereby these receptors modulate their effects in the brain.

Local GABAergic interneurons, the reticular nucleus and basal ganglia afferents from the internal globus pallidus (GPi) and the substantia nigra pars reticulata (SNr), are the main sources of GABAergic terminals to the CM/PF complex (Smith et al., 1987; Sidibé et al., 1997, 2002; Smith and Sidibé, 2003). The expression of presynaptic GABA<sub>B</sub> receptors at symmetric synapses (putative GABAergic) and in vesicle-filled dendrites of LCN dendrites in CM/PF suggests that activation of GABA<sub>B</sub> autoreceptors may reduce GABAergic transmission in this nuclear complex, a well-established physiological role for GABA<sub>B</sub> receptor in other thalamic nuclei (Soltesz and Cruonelli, 1992; Banerjee and Snead, 1995; Pape and McCormick, 1995; Williams et al., 1996; Emri et al., 1996; Ulrich and Huguenard, 1996; Sanchez-Vives et al., 1997).

Presynaptic labeling for GABA<sub>B</sub> receptors in glutamatergic terminals has been demonstrated in various brain regions, including the monkey basal ganglia (Charara et al., 2000, 2004, 2005; Smith et al., 2001; Galvan et al., 2004). Our findings revealed that such is also the case in monkey CM/PF, which is in line with electrophysiological observations that GABA<sub>B</sub> receptor activation presynaptically modulates glutamatergic transmission in the rat and mouse thalamus (Banerjee and Snead, 1995; Chen and Regehr, 2003). The high sensitivity of GABA<sub>B</sub> receptors for GABA (Sodickson and Bean, 1996) suggests that GABA spillover from GABAergic synapses (Atwell et al., 1993; Vogt and Nicoll, 1999; Scanziani, 2000) is the most likely mechanism of activation of these receptors.

Other sources of vGluT1-containing terminals in CM/PF that may be associated with GABA receptors are those from the brainstem pedunculopontine and the laterodorsal tegmental nuclei. Both of these nuclei provide substantial glutamatergic innervation to the monkey CM/PF (Sidibé et al., 2002; Smith and Sidibé, 2003). Additionally, there is good evidence that a large subset of glutamatergic inputs from these regions coexpresses vGluT1 and choline acetyltransferase (Smith and Paré, 2004), suggesting the potential corelease of glutamate and acetylcholine (ACh) at these synapses (Gutierrez, 2000, 2002). It is important to consider that functional interactions between GABA<sub>B</sub> and ACh muscarinic receptors have previously been reported for different CNS regions (Wichmann et al., 1987; Curro Dossi et al., 1992; Libri et al., 1998; Scanziani, 2000; Morton et al., 2001; Rowell et al., 2003).

GABA<sub>B</sub> receptors, CM/PF, and CNS pathologies

An increased GABAergic basal ganglia outflow from GPi and SNr to the thalamus is a cardinal feature in Parkinson’s disease (PD) pathophysiology (Palombo et al., 1990; Gao et al., 1997; Samuel et al., 1997; Bennazouz et al., 2000; Fukuda et al., 2001). The possibility that thalamic GABA<sub>B</sub> receptors play a role in PD is supported by results showing that the GABA<sub>B</sub> agonist baclofen induces akinesia when administrated locally in the ventromedial (VM) nucleus of the thalamus (DiChiara et al., 1979; Klockgether et al., 1986; Wullner et al., 1987). However, blockade of GABA<sub>B</sub> receptors in the VM of unilaterally 6-hydroxydopamine-lesioned rats does not have any effects on rotational behavior (de Groote et al., 1999), and binding studies could not find any significant changes in the number of GABA<sub>B</sub> binding sites in the thalamic ventral motor nuclei of MPTP-treated parkinsonian monkeys (Calon et al., 2000). Modulation of glutamatergic neuro-
transmission has beneficial effects in PD. In fact, systemic administration of glutamate antagonists in combination with subthreshold dose of L-DOPA has proved highly effective in reducing parkinsonian symptoms in animal models of PD (Loschmann et al., 1991; Greenamyer et al., 1994; Karcz-Kubicha et al., 1999). Results of this study and other studies demonstrate that GABA\(_B\) receptors are expressed in glutamatergic terminals at various sites along the basal ganglia-thalamostriatal circuitry. Knowing that increased glutamatergic tone on striatofugal or subthalamothalamic neurons is a key factor that underlies the pathophysiology of PD, one might consider GABA\(_B\) receptor activation as a potential venue for the development of novel pharmacotherapies in PD (Calon et al., 2000; Johnston and Duty, 2003).

Tourette’s syndrome (TS) is a chronic neurological disorder with an onset in early childhood that is characterized by different tics (sudden, brief, intermittent, involuntary, or semivoluntary movements or sounds). Although the cause of TS is unknown, and the precise neurobiological abnormality remains speculative (Mink, 2001; Singer and Minzer, 2003), bilateral coagulations (Hassler and Dieckmann, 1973) and chronic bilateral stimulation (Visser-Vandewalle, 2003) of the intralaminar thalamic nuclei produce a partial relief of tics in patients with TS, suggesting that overactivity of the intralaminar nuclei plays a major role in the TS. So far, drug treatment for TS consists of neuroleptics and other agents interacting with the dopaminergic system (Lavenstein, 2003). In fact, benzodiazepines, which enhance the inhibitory effect of GABA, have some efficacy in tic suppression (Gonç and Barbeau, 1977). However, these treatments have different side effects, such as depression, drowsiness, weight gain, and extrapyramidal symptoms. The strong expression of GABA\(_B\) receptors in CM/PF combined with their modulatory functions in the CNS opens up the possibility for new GABA\(_B\)-mediated pharmacotherapies for TS.

**CONCLUSIONS**

In conclusion, our results provide a solid framework for the involvement of GABA\(_B\) receptors in the pre- and postsynaptic regulation of GABAergic and glutamatergic transmission in the monkey caudal intralaminar thalamic complex. Given that the main target of CM/PF neurons is the striatum, our findings strongly suggest that GABA\(_B\) receptors play a major role in modulatory activity of the thalamostriatal system in primates. Future studies are needed to dissect out the mechanisms by which GABA\(_B\) receptor activation modulates excitatory and inhibitory synaptic transmission in CM/PF.

**ACKNOWLEDGMENTS**

The authors thank Mr. C. Heilman and Mab Technologies for the generous gift of rabbit anti-rat vGlut1 antibodies and J.-F. Paré, M. Verreault, and S. Maxson for technical assistance.

**LITERATURE CITED**


Banerjee PK, Sned OC 3rd. 1995. Presynaptic gamma-hydroxybutyric acid (GHB) and gamma-amino butyric acid (GABA\(_B\)) receptor-mediated release of GABA and glutamate (GLU) in rat thalamic ventrobasal nucleus (VB): a possible mechanism for the generation of absence-like seizures induced by GHB. J Pharmacol Exp Ther 273:1534–1543.


Calver AR, Michalovich D, Testa TT, Robbins MJ, Jallard C, Hill J,
GABA<sub>B</sub> RECEPTORS IN THE MONKEY THALAMUS


Soltesz I, Crusell M, Flor PJ. 1995. The gamma 2 subunit of the GABA_{A} receptor is concentrated in synaptic junctions containing the alpha 1 and beta 2/3 subunits in hippocampus, cerebellum and globus pallidus. Neuropharmacology 35:1425–1444.